全文获取类型
收费全文 | 81280篇 |
免费 | 7865篇 |
国内免费 | 4875篇 |
学科分类
医药卫生 | 94020篇 |
出版年
2024年 | 103篇 |
2023年 | 1077篇 |
2022年 | 1719篇 |
2021年 | 3942篇 |
2020年 | 3137篇 |
2019年 | 2787篇 |
2018年 | 2863篇 |
2017年 | 2692篇 |
2016年 | 2590篇 |
2015年 | 3877篇 |
2014年 | 4724篇 |
2013年 | 4609篇 |
2012年 | 6657篇 |
2011年 | 7094篇 |
2010年 | 4700篇 |
2009年 | 3854篇 |
2008年 | 4770篇 |
2007年 | 4714篇 |
2006年 | 4459篇 |
2005年 | 3984篇 |
2004年 | 3000篇 |
2003年 | 2813篇 |
2002年 | 2298篇 |
2001年 | 1883篇 |
2000年 | 1694篇 |
1999年 | 1573篇 |
1998年 | 867篇 |
1997年 | 836篇 |
1996年 | 619篇 |
1995年 | 546篇 |
1994年 | 500篇 |
1993年 | 278篇 |
1992年 | 448篇 |
1991年 | 329篇 |
1990年 | 309篇 |
1989年 | 287篇 |
1988年 | 247篇 |
1987年 | 215篇 |
1986年 | 180篇 |
1985年 | 144篇 |
1984年 | 91篇 |
1983年 | 73篇 |
1982年 | 33篇 |
1981年 | 50篇 |
1980年 | 29篇 |
1979年 | 45篇 |
1978年 | 26篇 |
1976年 | 35篇 |
1974年 | 30篇 |
1973年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 389 毫秒
1.
2.
人工智能(Artificial Intelligence,AI)的蓬勃兴起为现代社会带来了前所未有的机遇,中医药是中华民族传承千年的文化瑰宝。随着人工智能技术不断在中医药领域的科技创新中崭露头角,二者的融合不断加深,人工智能在中医药领域的发展前景、争议挑战也引发了诸多思考。本文将从人工智能在中医药领域的应用入手,对人工智能辅助中医诊断、智能决策与数据挖掘、健康管理及中草药现代化研究等方面,就近年来国内外研究进展进行总结与分析,以期为AI视域下实现中医药现代化、智能化赋能。 相似文献
3.
目的:探讨姑息性胃切除联合术后化疗评分在腹膜转移的胃癌患者预后评估中的临床意义。方法:回顾性分析2010年1月至2016年12月7年间收治的287例发生腹膜转移的胃癌患者的临床病理资料。通过χ2检验分析评分与患者临床病理因素间的关系。通过Kaplan-Meier法绘制生存曲线,Log-rank检验比较患者生存率的差异;采用Cox比例风险回归模型对患者进行预后分析。结果:与评分中得分为2分和1分的患者相比,得分为0分的患者肿瘤侵润至T4b 期的患者较少[31%(18/58)比50.8%(63/124)、56.2%(59/105),P=0.039]。全组患者的中位生存时间仅为8.7月。对患者进行单因素预后分析结果显示,血清白蛋白浓度(≤40 g/L),腹水,腹膜转移范围较大,肿瘤T分期较晚,评分得分较高的患者预后较差(均P<0.05)。将上述因素纳入Cox多因素分析结果显示:评分[HR(95%CI):1.384(1.165~1.644),P=0.000],血清白蛋白浓度[HR(95%CI):0.759(0.593~0.971),P=0.028],肿瘤T分期[HR(95%CI):1.493(1.216~1.832),P=0.000]是患者预后的独立危险因素。结论:评分对于胃癌伴腹膜转移患者的预后生存评估具有重要的临床意义。 相似文献
4.
Kuo-yi Jade Chang MHealthEc MHM BSc Lisa Lorraine Dillon MSpecEd BPsych Lil Deverell COMS PhD MEd GradDipO&M BEd Mei Ying Boon PhD BOptom FAAO Lisa Keay PhD MPH BOptom 《Clinical & experimental optometry》2020,103(4):434-448
Despite orientation and mobility (O&M) being a significant factor determining quality of life of people with low vision or blindness, there are no gold standard measures or agreement on how to measure O&M performance. In the first part of this systematic review, an inventory of O&M outcome measures used by recent studies to assess the performance of orientation and/or mobility of adults with vision impairment (low vision and blindness) is presented. A wide variety of O&M outcome measures have been implemented in different fields of study, such as epidemiologic research and interventional studies evaluating training, assistive technology, vision rehabilitation and vision restoration. The most frequent aspect of outcome measures is efficiency such as time, distance, speed and percentage of preferred walking speed, followed by obstacle contacts and avoidance, and dis/orientation and veering. Other less commonly used aspects are target identification, safety and social interaction and self-reported outcome measures. Some studies employ sophisticated equipment to capture and analyse O&M performance in a laboratory setting, while others carry out their assessment in real-world indoor or outdoor environments. In the second part of this review, the appropriateness of implementing the identified outcome measures to assess O&M performance in clinical and functional O&M practice is evaluated. Nearly a half of these outcome measures meet all four criteria of face validity (either clinical or functional), responsiveness, reliability and feasibility and have the potential to be implemented in clinical or functional O&M practice. The findings of this review confirm the complicated and dynamic nature of O&M. Multiple measures are required in any evaluation of O&M performance to facilitate holistic assessment of O&M abilities and limitations of each individual. 相似文献
7.
文题释义:
细胞膜片技术:是在体外接种培养高密度的细胞,使其相互融合生长至100%而形成的透明致密膜状物。该技术不需要胰酶消化即可收集细胞,因此保留了大量的胞外基质、细胞间连接以及细胞-基质连接等结构。目前细胞膜片技术已成为组织工程领域的研究热点,已被推广应用于牙周膜、角膜、心脏、软骨、食管等多种组织器官修复。
成骨细胞:主要由内外骨膜和间充质始祖细胞分化而来,在复杂的骨形成过程中发挥着主要的功能,承担着骨基质的合成、分泌和矿化。骨髓间充质干细胞具有多向分化潜能,能定向分化为成骨细胞,其成骨分化过程可受多种因素的影响,如细胞因子的调控、遗传因素和激素水平等。背景:现阶段骨形态发生蛋白2和碱性成纤维生长因子2对骨髓间充质干细胞膜片增殖、成骨分化的影响和作用机制还尚未可知,如何将生长因子与组织工程细胞膜片技术相整合,最终将其用于骨缺损修复具有重要意义。
目的:探讨单独及联合应用骨形态发生蛋白2和碱性成纤维生长因子2对骨髓间充质干细胞膜片增殖和成骨分化的影响。
方法:体外分离培养鉴定SD大鼠骨髓间充质干细胞并构建细胞膜片,选用不同质量浓度的骨形态发生蛋白2和碱性成纤维生长因子2单独及联合诱导骨髓间充质干细胞膜片,CCK-8法结合碱性磷酸酶活性检测确定2种因子促进膜片增殖和成骨分化的最佳有效质量浓度;然后对骨髓间充质干细胞膜片进行成骨诱导,通过大体及显微镜观察、Vonkossa染色、茜素红染色、RT-PCR检测相关成骨标志物来评估诱导效果。
结果与结论:单独应用骨形态发生蛋白2可增强骨髓间充质干细胞膜片的碱性磷酸酶活性,最佳质量浓度为100 μg/L(P < 0.001),单独应用碱性成纤维生长因子2能加速骨髓间充质干细胞膜片的增殖,最佳质量浓度为20 μg/L(P < 0.001),而联合应用既可以促进膜片增殖又能提高其碱性磷酸酶活性(P < 0.001);经成骨诱导后,4组膜片在形态学上无明显差异,均能诱导骨髓间充质干细胞膜片的成骨分化,其中联合组钙结节最明显(P < 0.001),可显著促进膜片晚期成骨分化并抑制其早期成骨分化,具有明显的协同促进作用(P < 0.001)。结果表明,骨形态发生蛋白2和碱性成纤维生长因子2联合应用时具有协同作用,既可以促进骨髓间充质干细胞膜片增殖,又能显著增强其成骨诱导能力。ORCID: 0000-0003-1918-579X(何惠宇)
中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程 相似文献
8.
9.
Jingjing He Lingyi Zhang Dan Guo Xingwen Han Hui Zhang Liang Wang Youcheng
Zhang 《Oncologie》2020,22(1):1-12
Hepatocellular carcinoma (HCC) ranks the sixth place of most common
cancers. Meanwhile, it is the tertiary mortality cause of cancer. There is no
effective therapeutic method to prevent and treat the liver cancer. Sinomenine is a
kind of Chinese traditional medicine herbal, it is reported that it can inhibit the
viability of several cancer cells. The study is to explore whether sinomenine is also
able to inhibit the cell viability of HCC and its potential mechanism. The IC50 of
sinomenine in BEL-7402 cells was 5.351 mmol/L, and the IC50 of sinomenine in
SMMC-7721 cells was 6.204 mmol/L. The gene expression results showed the
relative expression of FGF2, CCND2, DCN, F3, MMP7, NRG1, HMGB1,
TRIM29, HAS2, EHF, CTGF, PLK2 were down-regulated, and the relative
expression of VEGF A, CITED2, NUPR1, DDX58, IRF9, NAMPT, MMP1,
NDRG1, HMGA2, PPARGC1A, IFIT2, PARP9, HEY1, LOX, ETV1, ISG15,
BACH, CYLD were up-regulated. Moreover, the IPA analysis results suggested
that IFIT3, IFIT1, OAS1, MX1, IRF9, IFI6, IFITM1, ISG15 were up-regulated in
BEL-7402 cells treated with sinomenine by activating IFNA2. The findings
presented in this study may provide a promising method for the prevention and
treatment of liver cancer. 相似文献
10.
Bo Cai Qiyun Sun Jianhui Qiao Changlin Yu Kaixun Hu Tieqiang Liu Bingxia Li Yajing Huang Yi Wang Hongli Zuo Zheng Dong Yaqing Lei Zhiqing Liu Bo Yao Caixia Li Huisheng Ai Mei Guo 《American journal of cancer research》2020,10(11):3852
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) have poor prognosis, and the efficacy of chemotherapy plus tyrosine kinase inhibitors (TKIs) followed by mismatched donor stem cell infusion (microtransplantation, MST) has not been determined. We retrospectively summarized 45 patients including 11 undergoing MST with TKIs, 17 receiving allogeneic transplant and 17 undergoing chemotherapy with TKIs. Improved 4-year overall survival rate was observed in the MST group (91%) compared with either transplant group (31%, P = .005) or chemotherapy group (36%, P = .013). The MST group also had higher 2-year and 4-year leukemia-free survival rates (91% and 72%, respectively) compared with either transplant group (33%, P = .005 and 33%, P = .021, respectively) or chemotherapy group (41%, P = .017 and 31%, P = .023, respectively). 2-year and 4-year cumulative incidences of hematologic relapse were lower in the MST group (9% and 28%, respectively) compared with those in the chemotherapy group (56%, P = .025 and 67%, P = .034, respectively). In patients undergoing MST, donor microchimerism was detected (1.07 × 10-5 to 6.6 × 10-4 copies from 9 to 1499 days) in 7 patients, and donor/patient-derived HLA*0201/2402+WT1+CD8+ T cells were found from 0.05% to 0.67% in 6 patients. MST may provide a favorable treatment for patients with Ph+ ALL. 相似文献